QiagenQGEN
Market Cap: $9.89B
About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Employees: 5,900
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
130% more call options, than puts
Call options by funds: $47.9M | Put options by funds: $20.8M
66% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 35
29% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 89
8% more funds holding
Funds holding: 275 [Q1] → 298 (+23) [Q2]
8% more capital invested
Capital invested by funds: $5.75B [Q1] → $6.22B (+$468M) [Q2]
7.56% more ownership
Funds ownership: 60.74% [Q1] → 68.3% (+7.56%) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Baird Catherine Schulte 65% 1-year accuracy 11 / 17 met price target | 17%upside $52 | Outperform Maintained | 2 Aug 2024 |
Wolfe Research Doug Schenkel 63% 1-year accuracy 5 / 8 met price target | 12%upside $50 | Outperform Upgraded | 27 Jun 2024 |
JP Morgan Casey Woodring 80% 1-year accuracy 8 / 10 met price target | 21%upside $54 | Overweight Maintained | 18 Jun 2024 |
Financial journalist opinion
Based on 10 articles about QGEN published over the past 30 days